

1 **Title Page:**

2 **Metabolic dysfunction-associated steatohepatitis is associated with increased all-**  
3 **cause mortality**

4  
5 **Running title:** MASH can increase the risk of all-cause mortality

6  
7 Zhao Li<sup>1#</sup>, Rui Song<sup>2#</sup>, Yingzhi Zhang<sup>2#</sup>, Jiahe Tan<sup>3</sup>, Zhiwei Chen<sup>2\*</sup>

8  
9 <sup>1</sup> Department of Gastroenterology, the Seventh People's Hospital of Chongqing,  
10 Chongqing, China.

11 <sup>2</sup> Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of  
12 Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the  
13 Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

14 <sup>3</sup> Department of Neurosurgery, the First Affiliated Hospital of Chongqing Medical  
15 University, Chongqing, China.

16  
17 # These authors contribute equally to this work.

18 \* Corresponding author. Address: Institute for Viral Hepatitis, The Key Laboratory of  
19 Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The  
20 Second Affiliated Hospital of Chongqing Medical University, 74 Linjiang Road,  
21 Yuzhong District, Chongqing 400010, China. E-mail addresses:

22 zhiwei\_chen@cqmu.edu.cn.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23

24 **Author's email address:**

25 Zhao Li: 1546866602@qq.com

26 Rui Song: sr202099@163.com

27 Yingzhi Zhang: zhangyingzhi217@163.com

28 Jiahe Tan: tanjiahe1995@163.com

29 Zhiwei Chen: zhiwei\_chen@cqmu.edu.cn

30

31 **Data Availability Statement:** All the data in this study were available in the

32 NHANES III public database.

33

34 **Funding:** This work was supported by Remarkable Innovation-Clinical Research

35 Project, The Second Affiliated Hospital of Chongqing Medical University, and The

36 First batch of key Disciplines on Public Health in Chongqing, Health Commission of

37 Chongqing, China.

38

39 **Conflict of interest statement:** The authors declare no conflicts of interest.

40

41 **Ethics approval statement and patient consent statement:** NHANES III was

42 approved by the CDC/NCHS Ethics Review Board, and all individuals signed

43 informed consent to participate in NHANES III.

44

45 **Permission to reproduce material from other sources:** Yes.

46

47 **Clinical trial registration:** Not applicable.

48

49 **Word count:** 4026.

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

## Abstract

**Background:** Recently, the new nomenclature metabolic dysfunction-associated

steatohepatitis (MASH) was proposed to supersede non-alcoholic steatohepatitis

(NASH). To optimize the management of these patients, it is crucial to comprehend

the similarities and differences between individuals with NASH and MASH.

**Methods:** We analyzed data from 13,846 participants in the third National Health and

Nutrition Examination Surveys, along with their linked mortality through 2019.

NASH and MASH were defined based on respective criteria. Survey-weight adjusted

multivariable Cox proportional model was used to examine mortality.

**Results:** The overall prevalence of steatohepatitis, NASH and MASH was 5.7%

(n=788), 4.1% (n=564) and 5.5% (n=763), respectively. Most individuals with NASH

(96.8%) could be categorized as MASH, but only 69.7% individuals with MASH

qualified as NASH. During a median follow-up of 27 years, individuals with MASH

exhibited a 53% higher risk of all-cause mortality (adjusted hazard ratio [aHR] 1.53,

95% CI 1.24-1.89). But individuals with NASH didn't show an association with all-

cause mortality after adjustment for metabolic risk factors (aHR 1.14, 95% CI 0.91-

1.44). Notably, individuals who met the criteria for MASH but not NASH

(NASH(-)/MASH(+)) had a higher risk of all-cause mortality (aHR 2.47, 95% CI

1.71-3.57) compared to those with NASH(+)/MASH(+) (aHR 1.22, 95% CI 0.97-

1.55). Moreover, advanced fibrosis was only associated with an increased risk of all-

cause mortality in individuals with MASH, not NASH.

**Conclusions:** MASH, rather than NASH, was associated with an elevated risk of all-

cause mortality after adjusting for metabolic risk factors. Well-designed prospective studies are needed to assess and validate our findings.

**Key words:** NASH; MASH; mortality; NHANES III.

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidential intervals; FIB-4, fibrosis-4; HR, hazard ratio; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction associated steatotic liver disease; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NHANES III, Third National Health and Nutrition Examination Survey; NFS, NAFLD fibrosis score; PIR, poverty impact ratio.

## Introduction

The most severe form of nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), significantly heightens the risk of developing cirrhosis and liver cancer<sup>1</sup>. Although the prevalence of NASH is relatively low compared to NAFLD, it is witnessing a global upsurge<sup>2</sup>. Recently, the nomenclature for NAFLD has been updated to metabolic dysfunction associated steatotic liver disease (MASLD)<sup>3</sup>, with NASH now designated as metabolic dysfunction-associated steatohepatitis (MASH). However, whether MASH exhibits similar characteristics or clinical outcomes as NASH remains ambiguous. Consequently, it is imperative to address these questions to optimize management strategies for individuals with MASH.

Compared with NAFLD, MASLD places greater emphasis on the influence of metabolic factors (meeting at least one of the five cardio-metabolic adult criteria, without the constraints of alcohol consumption or viral hepatitis)<sup>3</sup>. Our previous study, as well as those of others, have demonstrated a high concurrence between NAFLD and MASLD<sup>4-8</sup>. Nevertheless, the similarities and differences between NASH and MASH remain obscure. As per the definition<sup>3</sup>, it is speculated that individuals who met NASH definition but not MASH might lack or exhibit mild metabolic risk factors, whereas, those with MASH but not NASH are likely to present with more metabolic risk factors, heavier alcohol consumption, or coexistence of viral hepatitis (hepatitis B or hepatitis C). Although the incidence of discordant subgroups that fulfill the criteria for one but not the other between NASH and MASH might be rare<sup>9</sup>, concrete data is currently lacking.

A previous investigation utilizing the data from the Third National Health and Nutrition Examination Survey (NHANES III) reported that NASH was not associated with an elevated mortality rate over a 15-year follow-up period<sup>10</sup>. However, the potential impact of extending the follow-up duration on the outcomes remains undefined. Moreover, it is unclear whether MASH or the discordant subgroups exhibit differing risks of all-cause and cause-specific mortality compared to NASH, necessitating further exploration.

In this study, we employed data from NHANES III, with a 27-year follow-up period, to compare the similarities and differences in clinical features and long-term mortality between individuals with non-alcoholic steatohepatitis and metabolic dysfunction-associated steatohepatitis.

## **Participants and Methods**

### **Study participants**

In this study, we utilized data from the NHANES III (1988-1994), a comprehensive, stratified, clustered, multi-staged probability sampling design national survey that accurately represents the entire US population<sup>11</sup>. The outcomes of interviews, physical examinations, and laboratory tests on participants with available liver ultrasonography data were collected and analyzed. This mainly encompassed demographic indices (e.g., sex, age, race, education, smoking or drinking status, concomitant disease etc.), anthropometric indices (e.g., body mass index (BMI), waist circumference, etc.), and laboratory tests (e.g., alanine aminotransferase (ALT), aspartate aminotransferase

(AST), and triglyceride, etc.). The NHANES mortality follow-up was a prospective study that dynamically assessed the vital status of all participants ( $\geq 20$  years). Cause-specific and all-cause mortality data were obtained from the National Death Index up to December 2019<sup>12</sup>. Detailed information on data collection and mortality evaluation is provided in the supplementary materials. All individuals participating in NHANES III signed informed consent.

### **Definition of NASH, MASH, and Fibrosis**

As liver biopsies were not obtained in NHANES III, steatohepatitis was defined as mild to severe hepatic steatosis with elevated liver enzymes levels based on a previous study<sup>10</sup>. NASH was defined as the presence of steatohepatitis in the absence of excessive alcohol consumption ( $\geq 20$  g/d for females and  $\geq 30$  g/d for males) and/or other liver diseases (such as viral hepatitis)<sup>10</sup>. MASH was defined by the presence of steatohepatitis in conjunction with at least one of the five cardio-metabolic adult criteria<sup>3</sup>. The detailed cardio-metabolic criteria are provided in the supplementary materials. We further categorized concordant NASH(+)/MASH(+) individuals as those who met both NASH and MASH definitions, while NASH(-)/MASH(-) individuals satisfied neither NASH nor MASH criteria. For the discordant subgroups, individuals fulfilling the NASH definition but not MASH were labeled as NASH(+)/MASH(-), and vice versa for those meeting MASH but not NASH, who were defined as NASH(-)/MASH(+). Finally, individuals without hepatic steatosis were designated as the control group.

Due to the unavailability of liver biopsy for direct assessment of fibrosis stage, we

employed various non-invasive fibrosis scores as alternatives. The NAFLD fibrosis score (NFS) and fibrosis-4 (FIB-4) score were selected based on prior studies<sup>13,14</sup>, which can be further categorized into low, intermediate, and high probabilities for advanced fibrosis. We defined advanced fibrosis as individuals presenting at least one of the two scores indicating a high probability of advanced fibrosis.

## **Statistical analysis**

The data are presented as median and interquartile range (IQR) for continuous variables, unweighted frequency counts and weighted percentage for categorical variables. The Wilcoxon test was employed for continuous variables, while the chi-square test was utilized for categorical variables. Cox proportional hazards regression was employed to estimate hazard ratios (HR) and 95% confidence intervals (CI) for deaths from all-causes and cause-specific (cardiovascular disease and cancer). We utilized two models with progressive degrees of adjustment: model 1 adjusted for demographic indices (sex, age, race, marital status, education, poverty impact ratio (PIR), healthy eating index (HEI) scores, sedentary lifestyle, and smoking status), while model 2 further adjusted for metabolic risk factors (BMI, waist circumference, triglycerides, and high-density lipoprotein cholesterol). For sensitivity analysis, firstly, to assess the impact of hepatic steatosis severity, we excluded individuals with mild hepatic steatosis from those with hepatic steatosis. Secondly, to avoid the potential confounding effect of viral hepatitis, we excluded participants with hepatitis B or hepatitis C from the entire population. All analyses were conducted using R (version 4.3.0; R Foundation for Statistical Computing, Vienna, Austria), with the survey package employed to account for the

sampling weights and the complex survey design in the NHANES III.

## Results

### Characteristics of individuals with NASH or MASH

Of the 14,797 participants (20-74 years) who underwent hepatic/gallbladder ultrasound examinations in the NHANES III, 941 individuals were excluded due to ungradable or missing ultrasound images. In addition, 10 participants without follow-up data on mortality were also excluded. Consequently, 13,846 participants from NHANES III were included in this study (Table S1). The overall prevalence of steatohepatitis, NASH, and MASH were 5.7% (n=788), 4.1% (n=564), and 5.5% (n=763), respectively. To focus on steatohepatitis more effectively, individuals with hepatic steatosis and normal liver enzyme levels (n=4,225) were further excluded from the entire population. Ultimately, a total of 9,621 individuals were included for subsequent analyses. Compared to individuals without hepatic steatosis, those with steatohepatitis were more likely to be older, male, non-Hispanic black, less educated, poorer, have increased liver enzyme levels, and exhibit metabolic abnormalities (Table 1). Of note, a significant majority individuals with NASH (96.8%) can be classified as MASH, yet only 69.7% of those with MASH can be qualified as NASH. Specifically, of the 788 individuals diagnosed with steatohepatitis, 69.3% of the subjects were assigned to the NASH(+)/MASH(+) subgroup, followed by NASH(-)/MASH(+), NASH(+)/MASH(-), and NASH(-)/MASH(-) subgroups (27.5%, 2.3%, and 0.9%, respectively; Figure 1). Notably, the subgroups characterized by MASH(+) exhibited

elevated coexisting metabolic risk factors, while those characterized by NASH(-) demonstrated higher alcohol consumption and proportion of viral hepatitis, particularly in the NASH(-)/MASH(+) subgroup (Table S2).

# **All-cause and cause-specific mortality of individuals with NASH or MASH**

During the median follow-up period of 27.0 years (23.3-29.0), the cumulative mortality rate from all-cause was 32.3% (3,105 deaths). Cause-specific mortality was attributed to cardiovascular disease and cancer, accounting for 8.5% (816 deaths) and 8.1% (777 deaths), respectively. As shown in Table 2, individuals with NASH exhibited a 1.3-fold increased risk of all-cause mortality compared to those without NASH (HR 1.29, 95% CI 1.01-1.65). After adjusting for demographic and traditional risk factors, the association between NASH and all-cause mortality remained significant (Model 1: adjusted HR [aHR] 1.41, 95% CI 1.14-1.74). However, this association was attenuated when further adjusting for metabolic risk factors (Model 2: aHR 1.14, 95% CI 0.91-1.42). Notably, individuals with MASH exhibited higher all-cause mortality rate than those without MASH in both models (Model 1: aHR 1.74, 95% CI 1.44-2.1; Model 2: aHR 1.53, 95% CI 1.24-1.89). Intriguingly, subgroup analysis revealed that only the NASH(-)/MASH(+) and NASH(-)/MASH(-) subgroups demonstrated significantly elevated all-cause mortality rates compared to individuals without hepatic steatosis in model 2 (aHR 2.47, 95% CI 1.71-3.57; aHR 3.65, 95% CI 1.48-9.04). The concordant NASH(+)/MASH(+) subgroup showed no association with all-cause mortality after further adjusting for metabolic risk factors (aHR 1.22, 95% CI 0.97-1.55). (Table 2)

Regarding cause-specific mortality, neither NASH nor MASH, nor their combined

subgroups demonstrated an association with cardiovascular mortality (Model 2: aHR 0.74-1.43) or cancer mortality (Model 2: aHR 1.25-1.87; Table 3).

### **The effect of fibrosis on all-cause mortality in individuals with NASH or MASH**

Given that individuals with NASH have a higher propensity to develop fibrosis than those with NAFLD<sup>15</sup>, we ponder whether such fibrosis augments the risk of all-cause mortality in NASH or MASH patients. Interestingly, advanced fibrosis was merely associated with an elevated risk of all-cause mortality in individuals with MASH, but not NASH (Model 2: aHR 1.7, 95% CI 1.12-2.58, p=0.012; aHR 1.39, 95% CI 0.86-2.22, p=0.2; Table 4). In particular, both the NFS and FIB-4 scores demonstrated a graded increase in the risk of all-cause mortality in individuals with MASH. That is, compared to the low probability subgroup, the high probability of advanced fibrosis subgroup exhibited a higher risk of mortality than the intermediate probability subgroup (NFS score: aHR 2.05, 95% CI 1.1-3.83; aHR 3.23, 95% CI 1.32-7.88; FIB-4 score: aHR 1.42, 95% CI 0.87-2.32; aHR 2.62, 95% CI 1.26-5.41). A similar trend was also observed in the NFS score of individuals with NASH (aHR 2.12, 95% CI 1.06-4.25; aHR 2.32, 95% CI 1.02-5.3), whereas, no such discrepancy was detected in the FIB-4 score. (Table 4)

### **Sensitivity analyses for individuals with NASH or MASH**

First, we wonder whether the hepatic steatosis degrees could affect the clinical outcomes. After excluded individuals with mild hepatic steatosis from those with hepatic steatosis, similar findings of mortality outcomes were observed (Table S3-5). Second, to avoid the potential confounding effect of viral hepatitis, we excluded

individuals with hepatitis B or hepatitis C from the whole population. In this scenario, the increased all-cause mortality was also observed in individuals with MASH, and NASH(-)/MASH(+) and NASH(-)/MASH(-) subgroups (Table S6). For the cause-specific mortality, the cardiovascular and cancer mortality were also not associated with both NASH or MASH and their combinations (Table S7). Even though the high NFS and FIB-4 scores subgroups still showed higher risk of all-cause mortality among individuals with MASH, the difference was not significant in increased all-cause mortality in MASH individuals with advanced fibrosis, after excluded participants with viral hepatitis (Model 2: aHR 1.41, 95% CI 0.99-2.03, p=0.059; Table S8).

Firstly, we examined the potential impact of hepatic steatosis severity on clinical outcomes. By excluding individuals with mild hepatic steatosis from those with hepatic steatosis, we observed similar mortality outcomes (Table S3-5). Secondly, to mitigate the potential confounding influence of viral hepatitis, we excluded individuals with hepatitis B or hepatitis C from the study population. In this context, increased all-cause mortality was also noted in individuals with MASH, as well as in the NASH(-)/MASH(+) and NASH(-)/MASH(-) subgroups (Table S6). Regarding cause-specific mortality, cardiovascular and cancer mortality were not associated with both NASH and MASH, nor with their combinations (Table S7). Although individuals with MASH in the high NFS and FIB-4 score subgroups exhibit a higher risk of all-cause mortality, the increased risk of all-cause mortality among MASH patients with advanced fibrosis does not reach statistical significance, after excluding participants with viral hepatitis (Model 2: aHR 1.41, 95% CI 0.99-2.03, p=0.059; Table S8).

## Discussion

The recent proposal of the new nomenclature MASH to replace NASH necessitates a thorough understanding of the similarities and differences between individuals with NASH and MASH, in order to optimize the management of these patients. In this study, although patients with NASH exhibited similar clinical features regarding metabolic risk factors compared to those with MASH, it was found that MASH, not NASH, was significantly associated with an increased all-cause mortality after adjusting for metabolic risk factors. Additionally, advanced fibrosis in patients with MASH was associated with a higher risk of all-cause mortality compared to those with NASH. These findings imply that independent of metabolic risk factors, there exists a strong correlation between MASH and an increase in all-cause mortality.

NASH can contribute to progressive fibrosis, and in some cases, cirrhosis or even liver cancer<sup>1</sup>. However, a previous study found no correlation between NASH and an increase in all-cause mortality following a 15-year follow-up in NHANES III<sup>10</sup>. Using a longer follow-up period (27 years), we reiterated that NASH per se is not associated with all-cause mortality after adjusting for metabolic risk factors. Notably, in contrast to the previous study<sup>10</sup>, NASH increases the risk of all-cause mortality when only adjusting for demographic and traditional risk factors (model 1), but not metabolic risk factors. Although the definition of NASH does not encompass metabolic risk, individuals with NASH exhibit similar metabolic characteristics to those with MASH in this study. Consequently, caution should be exercised for the long-term prognosis of

individuals with NASH, particularly those with a high risk of concurrent conditions (e.g., type 2 diabetes mellitus<sup>16</sup> or liver cirrhosis<sup>17</sup>). Nevertheless, individuals with MASH exhibit a 53% higher risk of all-cause mortality than those without MASH even after adjusting for metabolic risks. This suggests that MASH can identify individuals with a higher risk of all-cause mortality than NASH. Therefore, greater attention and early intervention are warranted for those with MASH, such as lifestyle modification<sup>18,19</sup>, or other novel therapies<sup>20,21</sup>.

When we further categorized individuals with steatohepatitis into four subgroups, interesting findings regarding all-cause mortality emerged. In Model 1, individuals with NASH(+)/MASH(+) exhibited a 47% increased risk of all-cause mortality, which disappeared after further adjusting for metabolic risk factors. This suggests that metabolic factors play a significant role in the elevation of all-cause mortality risk for these individuals. Notably, individuals with NASH(-)/MASH(+) still exhibited a 2.47-fold risk of all-cause mortality even after adjusting for metabolic risk factors. This indicates that, beyond metabolic factors, heavy alcohol consumption and/or viral hepatitis may have a more potent impact on the risk of all-cause mortality for MASH patients<sup>22,23</sup>. After excluding individuals with viral hepatitis in the sensitivity analysis, the high all-cause mortality risk persisted. This suggests that significant alcohol consumption, rather than viral hepatitis, could be responsible for the increased all-cause mortality risk. However, this should be interpreted with caution due to the small sample size. Larger studies are needed to verify these findings in the future. A similar phenomenon was also observed in individuals with NASH(-)/MASH(-), although the

sample size was smaller. This subgroup represents a relatively small proportion of individuals with concurrent liver disease but without metabolic comorbidities. After excluding individuals with viral hepatitis, this discordant group may be attributed to alcoholic steatohepatitis (ASH), which could contribute to the interpretation of the increased risk of all-cause mortality<sup>24</sup>. Therefore, based on these observations, it is crucial to distinguish between MASH with concurrent liver disease and its absence in future studies.

In this study, a significant majority of patients with NASH (96.8%) are classified as MASH, with only 3.2% lacking metabolic risk factors. This finding is consistent with a previous review<sup>9</sup>, and supports the retention and validity of historical data from NASH clinical trials. However, the situation becomes distinct when reversed. As it is not a prerequisite to exclude concurrent liver diseases for the diagnosis of MASH, MASH may encompass a broader range of individuals with various liver disease etiologies (viral, alcoholic, autoimmune, genetic, etc.), akin to MASLD<sup>3</sup>. Specifically, only 69.7% of individuals with MASH can be confirmed as having NASH, suggesting that 30.3% of these individuals harbor alternative etiologies (excessive alcohol consumption and/or viral hepatitis) in this analysis. The gap may vary with differing population selection. Moreover, in this context, it appears challenging to differentiate between MASH and hepatitis induced by other etiologies (e.g., ASH or active viral hepatitis). This could potentially impact the risk of all-cause mortality for these patients directly, as mentioned above. From this aspect, it may be advantageous to appropriately refine or qualify the new term of MASH in order to mitigate this ambiguity.

To our knowledge, no study has previously evaluated the association between MASH and mortality. This is the strength of our study. However, there are several limitations to our study. First, although this is a nationally representative study based on the NHANES III dataset (1988-1994), the low prevalence of steatohepatitis at that time resulted in a relatively small sample of patients with NASH or MASH. Large-sample studies focusing on these patients are needed to validate our observations. Second, steatohepatitis was not confirmed by liver biopsy but by ultrasound examination, which may underestimate the prevalence and impact on clinical outcomes of individuals with NASH or MASH<sup>25</sup>. However, the advantages of ultrasound, such as safety, affordability, sufficient sensitivity, and satisfactory specificity, make it suitable for use in large population-based epidemiologic studies<sup>26</sup>. Third, in the US population-based study, the prevalence of viral hepatitis (especially hepatitis B) was low, therefore, the results in this regard should be interpreted with caution. Further studies are needed to clarify the specific effect of viral hepatitis on the mortality of individuals with MASH, especially in high-prevalence areas of viral hepatitis, such as Asia and Africa<sup>27</sup>.

In summary, our research demonstrates for the first time a significant association between MASH and increased all-cause mortality, independently of metabolic and demographic risk factors. In contrast, NASH exhibits a heightened risk of all-cause mortality, while it becomes non-significant following adjustment for metabolic risk factors. Moreover, it is crucial to differentiate between individuals with concomitant liver disease and those without when studying MASH. In future, well-designed prospective studies with large sample sizes are needed to assess and validate our

findings.

**Acknowledgement:** We gratefully acknowledge the contribution of the participants of the NHANES cohort, research assistants, and facilitating personnel. And this work was supported by the Science and technology research project of Chongqing Education Commission (KJZD-K202300404), Remarkable Innovation-Clinical Research Project and the DengFeng Program of the Second Affiliated Hospital of Chongqing Medical University, and The First batch of key Disciplines on Public Health in Chongqing, Health Commission of Chongqing, China.

**Conflict of interest statement:** The authors declare no conflicts of interest.

### **Ethics approval statement**

The National Center for Health Statistics Research Ethics Review Board approved the NHANES protocol.

### **Data Availability Statement**

All data produced in the present study are available upon reasonable request to the authors.

**Author contributions:** Rui Song, Zhao Li and Yingzhi Zhang was involved in

acquisition of data, data analysis and interpretation, drafting of the manuscript, and study supervision. Jiahe Tan were involved in interpretation of data and critical revision of the manuscript. Zhiwei Chen was involved in study concept and design, interpretation of data, drafting of the manuscript, critical revision of the manuscript, and study supervision. All authors contributed to the article and approved the submitted version.

## Reference

1. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol.* 2021;18(4):223-238.
2. Brennan PN, Elsharkawy AM, Kendall TJ, Loomba R, Mann DA, Fallowfield JA. Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. *Nat Rev Gastroenterol Hepatol.* 2023;20(10):679-688.
3. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. *J Hepatol.* 2023.
4. Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. *Liver Int.* 2024;44(4):1051-1060.
5. Perazzo H, Pacheco AG, Griep RH. Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort. *J Hepatol.* 2024;80(2):e72-e74.

- 419 6. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet  
420 MASLD criteria and natural history is therefore identical. *J Hepatol.*  
421 2024;80(2):e76-e77.
- 422 7. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data  
423 under the new MASLD definition? *J Hepatol.* 2024;80(2):e54-e56.
- 424 8. Ratziu V, Boursier J. Confirmatory biomarker diagnostic studies are not needed  
425 when transitioning from NAFLD to MASLD. *J Hepatol.* 2024;80(2):e51-e52.
- 426 9. Yeh ML, Yu ML. From nonalcoholic steatohepatitis, metabolic dysfunction-  
427 associated fatty liver disease, to steatotic liver disease: Updates of nomenclature  
428 and impact on clinical trials. *Clin Mol Hepatol.* 2023;29(4):969-972.
- 429 10. Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and  
430 mortality among US adults: prospective cohort study. *Bmj.* 2011;343:d6891.
- 431 11. CfDCaP NCfHS. Analytic and reporting guidelines: The Third National Health  
432 and Nutrition Examination Survey, NHANES III (1988-94). 1996;  
433 [https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-](https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-reporting-guidelines.pdf)  
434 [reporting-guidelines.pdf](https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-reporting-guidelines.pdf) (Access on 2024.04.01).
- 435 12. Statistics NCfH. 2019 Public-Use Linked Mortality Files. 2022;  
436 <https://www.cdc.gov/nchs/data-linkage/mortality-public.htm> (Access on  
437 2024.04.01).
- 438 13. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a  
439 noninvasive system that identifies liver fibrosis in patients with NAFLD.  
440 *Hepatology.* 2007;45(4):846-854.

- 441 14. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison  
442 of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver  
443 disease. *Clin Gastroenterol Hepatol*. 2009;7(10):1104-1112.
- 444 15. Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. *Nat*  
445 *Rev Gastroenterol Hepatol*. 2023;20(10):633-646.
- 446 16. En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty  
447 liver disease in type 2 diabetes mellitus: an updated systematic review and meta-  
448 analysis. *Gut*. 2023;72(11):2138-2148.
- 449 17. Lim WH, Ng CH, Tan D, et al. Natural history of NASH cirrhosis in liver  
450 transplant waitlist registrants. *J Hepatol*. 2023;79(4):1015-1024.
- 451 18. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-  
452 alcoholic fatty liver disease. *J Hepatol*. 2016;64(6):1388-1402.
- 453 19. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of  
454 nonalcoholic fatty liver disease: Practice guidance from the American  
455 Association for the Study of Liver Diseases. *Hepatology*. 2018;67(1):328-357.
- 456 20. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of  
457 Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. *N Engl J Med*.  
458 2021;384(12):1113-1124.
- 459 21. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in  
460 Adults with Overweight or Obesity. *N Engl J Med*. 2021;384(11):989-1002.
- 461 22. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. *Nat Rev Dis*  
462 *Primers*. 2018;4(1):16.

463 23. You H, Wang F, Li T, et al. Guidelines for the Prevention and Treatment of  
464 Chronic Hepatitis B (version 2022). *J Clin Transl Hepatol*. 2023;11(6):1425-  
465 1442.

466 24. Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH.  
467 *Dig Dis*. 2011;29(2):202-210.

468 25. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease.  
469 *Gastroenterology*. 2002;123(5):1705-1725.

470 26. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging  
471 in nonalcoholic fatty liver disease. *Gastroenterology*. 2002;123(3):745-750.

472 27. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global  
473 burden of liver disease: 2023 update. *J Hepatol*. 2023;79(2):516-537.

474

475

476

477

478

479

480


481

482

483

484

**Figure and figure legend**



**Figure 1. Relative proportions of non-alcoholic steatohepatitis and metabolic dysfunction-associated steatohepatitis.** NASH(+)/MASH(+) was defined as individuals who met both NASH and MASH definitions. NASH(-)/MASH(-) was defined as individuals who met neither NASH nor MASH definitions. For the discordant subgroups, individuals meeting the definition of NASH but not MASH were defined as NASH(+)/MASH(-), while those meeting with MASH but not NASH were defined as NASH(-)/MASH(+).

499

500

**Table 1. Baseline characteristics of individuals with NASH or MASH.**

<b>Characteristics</b>	<b>No hepatic steatosis (n=8,833)</b>	<b>Steatohepatitis (n=788)</b>	<b>P</b>	<b>NASH (n=564)</b>	<b>MASH (n=763)</b>
Age (years)	38.0 (28.0, 51.0)	40.0 (33.0, 53.0)	0.003	40.0 (32.0, 52.0)	41.0 (33.0, 53.0)
Sex (male)	4,027 (47%)	445 (58%)	0.007	290 (55%)	429 (58%)
Race			<0.001		
Non-Hispanic white	3,293 (76%)	186 (66%)		138 (70%)	181 (67%)
Non-Hispanic black	2,829 (12%)	149 (8.6%)		318 (14%)	410 (14%)
Mexican-American	2,324 (4.8%)	421 (13%)		89 (6.6%)	141 (8.4%)
Others	387 (7.7%)	32 (12%)		19 (9.8%)	31 (11%)
Body mass index (kg/m <sup>2</sup> )	24.7 (22.1, 27.6)	30.0 (26.6, 35.1)	<0.001	30.6 (27.0, 35.6)	30.3 (27.1, 35.2)
Waist circumference (cm)	88 (79, 96)	104 (94, 112)	<0.001	105 (94, 112)	104 (94, 112)
≥12 years education	5,716 (79%)	389 (70%)	<0.001	284 (74%)	373 (69%)
Marital status	5,445 (66%)	493 (63%)	0.3	374 (66%)	484 (63%)
PIR	2.9 (1.7, 4.3)	2.3 (1.1, 3.8)	0.016	2.4 (1.2, 3.9)	2.2 (1.1, 3.9)
HEI score	63 (54, 73)	61 (53, 73)	0.4	63 (53, 74)	61 (53, 72)
Hypertension	2,458 (23%)	334 (49%)	<0.001	237 (47%)	334 (51%)
Diabetes	581 (3.9%)	170 (20%)	<0.001	134 (21%)	170 (21%)
Smoking status			0.004		
Never	4,341 (46%)	377 (45%)		310 (50%)	363 (44%)
Past smoker	1,824 (22%)	195 (30%)		148 (33%)	191 (31%)
Current smoker	2,668 (32%)	216 (24%)		106 (17%)	209 (25%)
Alcohol consumption (g/d)	4 (1, 12)	8 (2, 28)	0.003	3 (0, 10)	8 (2, 28)
Viral hepatitis (HBV/HCV)	242 (2.2%)	96 (10%)	<0.001	0	96 (11%)
Sedentary lifestyle	2,420 (19%)	261 (23%)	0.2	199 (24%)	256 (23%)

Triglycerides (mg/dL)	1.1 (0.8, 1.6)	1.9 (1.2, 3.2)	<0.001	2.1 (1.4, 3.6)	2.0 (1.3, 3.3)
HDL-cholesterol (mg/dL)	1.3 (1.1, 1.6)	1.1 (0.9, 1.4)	<0.001	1.0 (0.9, 1.3)	1.1 (0.9, 1.4)
Glucose (mol/L)	5.1 (4.8, 5.4)	5.4 (5.1, 6.2)	<0.001	5.4 (5.0, 6.1)	5.5 (5.1, 6.2)
ALT (U/L)	13 (10, 18)	47 (37, 63)	<0.001	47 (37, 63)	47 (36, 63)
AST (U/L)	18 (16, 22)	39 (33, 53)	<0.001	38 (31, 48)	39 (32, 53)

Data are shown as the median (interquartile range) or unweighted frequency counts (weighted percentage) as appropriate. The Wilcoxon test for continuous variables and the Chi-square test for categorical variables were used in this analysis.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; PIR, poverty impact ratio.

**Table 2. Association among NASH or MASH status and all-cause mortality.**

	N	n (deaths)	Univariable model		Multivariable Model 1		Multivariable Model 2	
			HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
No NASH	9057	2900	1		1		1	
NASH	564	205	1.29 (1.01-1.65)	0.042	1.41 (1.14-1.74)	0.001	1.14 (0.91-1.44)	0.2
No MASH	8858	2792	1		1		1	
MASH	763	313	1.8 (1.45-2.23)	<0.001	1.74 (1.44-2.1)	<0.001	1.53 (1.24-1.89)	<0.001
No hepatic steatosis	8833	2785	1		1		1	
NASH(+)/MASH(+)	546	203	1.41 (1.08-1.82)	0.01	1.47 (1.18-1.82)	<0.001	1.22 (0.97-1.55)	0.1
NASH(+)/MASH(-)	18	2	0.11 (0.02-0.61)	0.012	0.41 (0.07-2.44)	0.3	0.29 (0.03-2.77)	0.3
NASH(-)/MASH(+)	217	110	3.12 (2.39-4.06)	<0.001	2.51 (1.77-3.56)	<0.001	2.47 (1.71-3.57)	<0.001
NASH(-)/MASH(-)	7	5	4.02 (1.56-10.4)	0.004	3.01 (1.27-7.16)	0.012	3.65 (1.48-9.04)	0.005

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, race, marital status, education, PIR, HEI scores, sedentary lifestyle, and smoking status.

Multivariate model 2 was further adjusted for BMI, waist circumference, triglycerides, and high-density lipoprotein cholesterol in addition to model 1.

BMI, body mass index; CI, confidential intervals; HR, hazard ratio; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; PIR, poverty impact ratio.

**Table 3. Association among NASH or MASH status and cardiovascular disease and cancer-related mortality.**

	N	n (deaths)	Univariable model		Multivariable Model 1		Multivariable Model 2	
			HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Cardiovascular mortality								
No NASH	9057	778	1		1		1	
NASH	564	38	1.03 (0.68-1.57)	0.9	1.14 (0.78-1.67)	0.5	0.74 (0.48-1.13)	0.2
No MASH	8858	763	1		1		1	
MASH	763	53	1.29 (0.9-1.87)	0.2	1.25 (0.87-1.78)	0.2	0.87 (0.58-1.32)	0.5
No hepatic steatosis	8833	762	1		1		1	
NASH(+)/MASH(+)	546	38	1.11 (0.73-1.69)	0.6	1.17 (0.8-1.7)	0.4	0.76 (0.5-1.15)	0.2
NASH(+)/MASH(-)	18	0	/	/	/	/	/	/
NASH(-)/MASH(+)	217	15	1.88 (0.92-3.85)	0.085	1.48 (0.57-3.82)	0.4	1.43 (0.53-3.87)	0.5
NASH(-)/MASH(-)	7	1	0.34 (0.04-3.13)	0.3	0.27 (0.03-2.88)	0.3	0.87 (0.08-9.15)	>0.9
Cancer mortality								
No NASH	9057	732	1		1		1	
NASH	564	45	1.04 (0.63-1.71)	0.9	1.25 (0.74-2.11)	0.4	1.25 (0.73-2.14)	0.4
No MASH	8858	704	1		1		1	
MASH	763	73	1.42 (0.97-2.07)	0.073	1.43 (0.94-2.19)	0.1	1.48 (0.91-2.4)	0.11
No hepatic steatosis	8833	704	1		1		1	
NASH(+)/MASH(+)	546	45	1.13 (0.68-1.86)	0.6	1.29 (0.76-2.19)	0.3	1.32 (0.76-2.27)	0.3
NASH(+)/MASH(-)	18	0	/	/	/	/	/	/
NASH(-)/MASH(+)	217	28	2.35 (1.33-4.13)	0.003	1.78 (0.97-3.24)	0.062	1.87 (0.97-3.59)	0.062
NASH(-)/MASH(-)	7	0	/	/	/	/	/	/

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, race, marital status, education, PIR, HEI scores, sedentary lifestyle, and smoking status.

Multivariate model 2 was further adjusted for BMI, waist circumference, triglycerides, and high-density lipoprotein cholesterol in addition to model 1.

BMI, body mass index; CI, confidential intervals; HR, hazard ratio; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; PIR, poverty impact ratio.

**Table 4. Association of advanced fibrosis status and all-cause mortality among individuals with NASH or MASH.**

	N	n (deaths)	Univariable model		Multivariable Model 1		Multivariable Model 2	
			HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
NASH								
No advanced fibrosis	503	161	1		1		1	
Advanced fibrosis	55	43	4.39 (2.68-7.19)	<0.001	1.51 (0.92-2.47)	0.1	1.39 (0.86-2.22)	0.2
Low NFS	377	78	1		1		1	
Intermediate NFS	141	93	4.85 (2.60-9.03)	<0.001	2.65 (1.41-4.99)	0.002	2.12 (1.06-4.25)	0.033
High NFS	40	33	7.69 (3.55-16.7)	<0.001	3.11 (1.62-5.97)	<0.001	2.32 (1.02-5.30)	0.046
Low FIB-4	394	92	1		1		1	
Intermediate FIB-4	123	79	3.88 (2.31-6.52)	<0.001	1.45 (0.81-2.61)	0.2	1.35 (0.66-2.73)	0.4
High FIB-4	41	33	8.87 (5.36-14.7)	<0.001	1.62 (0.75-3.50)	0.2	1.95 (0.94-4.06)	0.074
MASH								
No advanced fibrosis	665	236	1		1		1	
Advanced fibrosis	91	75	4.37 (3.18-6.01)	<0.001	1.92 (1.27-2.91)	0.002	1.70 (1.12-2.58)	0.012
Low NFS	499	123	1		1		1	
Intermediate NFS	199	139	3.84 (2.38-6.19)	<0.001	2.55 (1.46-4.45)	<0.001	2.05 (1.10-3.83)	0.024
High NFS	58	49	7.38 (4.21-12.9)	<0.001	4.40 (2.21-8.73)	<0.001	3.23 (1.32-7.88)	0.01
Low FIB-4	501	126	1		1		1	
Intermediate FIB-4	180	121	3.05 (2.12-4.39)	<0.001	1.38 (0.89-2.14)	0.15	1.42 (0.87-2.32)	0.2
High FIB-4	75	64	8.01 (5.29-12.1)	<0.001	2.32 (1.26-4.27)	0.007	2.62 (1.26-5.41)	0.01

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, race, marital status, education, PIR, HEI scores, sedentary lifestyle, and smoking status.

Multivariate model 2 was further adjusted for BMI, waist circumference, triglycerides, and high-density lipoprotein cholesterol in addition to model 1.

BMI, body mass index; CI, confidential intervals; FIB-4, fibrosis-4; HR, hazard ratio; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; NFS, NAFLD fibrosis score; PIR, poverty impact ratio.